Gilead Sciences logo
Gilead Sciences
GILD | NASDAQ
Chart Builder DCF Calculator
$167.58
-$0.50 (-0.30%)
At close: Nov 16, 2026, 4:00 PM ET
$169.14
+$1.56 (+0.93%)
After-hours: Nov 16, 2026, 7:46 PM ET

Gilead Sciences Company Profile

Company profile explained

Company Profile

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.

Key Executives

Name Position
Daniel O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Executive VP & CFO
Dietmar Berger Chief Medical Officer
Erin Burkhart Senior VP, Controller & Chief Accounting Officer
Flavius Martin Executive Vice President of Research
Jacquie Ross Senior Vice President of Treasury and Investor Relations
Janet Dorling Senior Vice President of Intercontinental Region & Global Patient Solutions
Johanna Mercier Chief Commercial & Corporate Affairs Officer
Jyoti K. Mehra Executive Vice President of Human Resources
Keeley Wettan Executive VP, General Counsel of Legal & Compliance and Secretary
Linda Slanec Higgins Senior Vice President of Research, Innovation & Portfolio

Latest SEC Filings

Date Type Title
Oct 30, 2026 10-Q Quarterly Report
Oct 29, 2026 8-K Current Report
Oct 16, 2026 4 Filing
Oct 16, 2026 4 Filing
Oct 02, 2026 4 Filing
Sep 23, 2026 4 Filing
Sep 16, 2026 4 Filing
Sep 16, 2026 4 Filing
Sep 11, 2026 4 Filing
Sep 11, 2026 4 Filing
View All SEC Filings ➞
Gilead Sciences
Gilead Sciences logo
Country United States
IPO Date Jan 22, 1992
Industry Drug Manufacturers - General
Sector Healthcare
Employees 17,000
CEO Daniel O'Day

Contact Details

333 Lakeside Drive Foster City, California 94404 United States

Stock Details

Ticker Symbol GILD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000882095
CUSIP Number 375558103
ISIN Number US3755581036
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.